Table 1.
Baseline characteristics of patients
| (n=29) | |
| Age | |
| Median (range) | 70 (43–86) |
| Gender—no (%) | |
| Male | 22 (75.9) |
| Female | 7 (24.1) |
| Race—no (%) | |
| White | 25 (86.2) |
| Hispanic | 3 (10.3) |
| Asian/Pacific Islander | 1 (3.4) |
| Immunocompromised—no (%) | 3 (10.3) |
| ECOG performance status—no (%) | |
| 0 | 10 (34.5) |
| 1 | 15 (51.7) |
| 2 | 4 (13.8) |
| Primary tumor site—no (%) | |
| Head/neck | 16 (55.2) |
| Trunk | 8 (27.6) |
| Extremity | 5 (17.2) |
| Extent of disease—no (%) | |
| Locally advanced | 20 (69.0) |
| Metastatic | 9 (31.0) |
| Clinicopathological features—no (%) | |
| Recurrent tumor | 18 (62.1) |
| Poorly defined borders | 13 (44.8) |
| Perineural invasion | 6 (20.7) |
| Aggressive histology—no (%) | 19 (65.5) |
| Basosquamous | 8 (27.6) |
| Morpheaform | 4 (13.8) |
| Mixed | 3 (10.3) |
| Micronodular | 2 (6.9) |
| Other | 2 (6.9) |
| Anatomic site of metastases—no (%) | |
| Lung | 7 (24.1) |
| Lymph node | 6 (20.7) |
| Bone | 4 (13.8) |
| Liver | 1 (3.4) |
| Prior therapy—no (%) | |
| Surgery | 21 (72.4) |
| Radiation | 18 (62.1) |
| Hedgehog inhibitor | 24 (82.8) |
| Reason for discontinuing prior hedgehog inhibitor therapy—no (%) | |
| Progression of disease | 18 (75.0) |
| Adverse events | 3 (12.5) |
| Other | 3 (12.5) |
ECOG, Eastern Cooperative Oncology Group.